Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Royalty Pharma plc - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
RPRX
Nasdaq
2830
www.royaltypharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Royalty Pharma plc
MRK, RPRX Stocks Hit 52-Week Highs – What Drove Today’s Gains?
- Aug 25th, 2026 12:24 pm
Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?
- Aug 13th, 2026 4:27 pm
Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors
- Aug 13th, 2026 7:35 am
Zealand Pharma (CPSE:ZEAL) Stock Looks Fairly Valued After Its 90% Five Year Run
- Aug 13th, 2026 2:10 am
Zealand Pharma (CPSE:ZEAL) On Its Royalty Pharma Deal And The Fair Value Debate
- Aug 12th, 2026 5:16 pm
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
- Aug 12th, 2026 2:10 pm
Royalty Pharma (RPRX) Q2 2026 Earnings Call Transcript
- Aug 12th, 2026 7:59 am
Revolution Medicines Q2 Earnings Call Highlights
- Aug 5th, 2026 10:03 pm
Royalty Pharma Q2 Earnings Call Highlights
- Aug 5th, 2026 1:04 pm
Royalty Pharma PLC (RPRX) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance
- Aug 5th, 2026 1:01 pm
Royalty Pharma (RPRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
- Aug 5th, 2026 7:30 am
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
- Aug 5th, 2026 7:00 am
Royalty Pharma reports second quarter 2026 results
- Aug 5th, 2026 5:00 am
Gear Up for Royalty Pharma (RPRX) Q2 Earnings: Wall Street Estimates for Key Metrics
- Aug 4th, 2026 7:15 am
Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives
- Aug 3rd, 2026 6:15 am
Royalty Pharma (RPRX) Could Be 40% Undervalued After Its Dividend Decision
- Jul 30th, 2026 9:16 pm
Will Iovance Biotherapeutics (IOVA) Report Negative Q2 Earnings? What You Should Know
- Jul 30th, 2026 8:00 am
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Jul 29th, 2026 8:00 am
Scroll